Gold Resource Corp (NYSE:GORO) an ascending 3.98% to $5.23 with traded session volume was 1.95 Million. Gold Resource (GORO) acquired additional exploration mining claims, which consolidate the mineralized trend of its Isabella Pearl gold development project in Mineral County, Nevada.
The Company acquired 100% of 153 mining claims from Nevada Select for US$460,000, which included shares of restricted common stock valued at $300,000, and cash of $100,000, plus a one-time advanced royalty cash payment of $60,000. Nevada Select retained a net smelter return royalty (NSR) of 2.5% on the claims.
The Company has the right to buy down 0.5% percent of the NSR on the claims for US$500,000. The newly acquired mining claims brings the total number of mining claims at the project to 494, covering approximately 9,000 acres and which consolidate and eliminates many mine claim gaps along Isabella Pearl’s mineralized trend. The claims extend exploration potential to the northwest along a geologic trend with mineralized outcrops and historic mine workings. As concerns of stock price volatility, it was 10.24% for a week and 8.51% for a month.
Can Gold Resource Corp become the newest Buy stock following this news? Get Your Free Report Here
VCA Inc. (NASDAQ:WOOF) ascend 28.29% during the previous trading session as the firm held price to earnings ratio of 31.92. VCA (WOOF) to be acquired by Mars Inc. for $93/share, or approximately $9.1 billion. The firm reported that they have entered an contract under which Mars will acquire all of the outstanding shares of VCA for $93 per share, or a total value of approximately $9.1 billion including $1.4 billion in outstanding debt. The transaction price represents a premium of 41% over VCA’s 30-day volume weighted average price on January 6, 2017.The company will remain headquartered in Los Angeles, California and will remain focused on its business model and strategic objectives.
Can investors take a chance on buying WOOF this week? Find Inside Facts Here
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) keeps its position active in street, shares closed at $23.75 with shows upbeat performance surges of 72.85%. AriadPharma (ARIA) plans to be acquired by Takeda (TKPYY) for $24/share in cash, or approximately $5.2 billion. The transaction is a compelling opportunity for Takeda shareholders. It will provide immediate revenue, bring considerable long-term income potential and deliver synergy savings.
ARIAD provided calendar year 2016 income guidance for Iclusig of $170-180 million, and Takeda expects important long-term income potential from the two lead assets. Takeda projects the acquisition of ARIAD to be accretive to Underlying Core Earnings by FY2018 and broadly neutral in FY2017. Strong income growth and synergy savings will offset surged sales and marketing costs for the brigatinib launch. The transaction is expected to close by the end of February 2017. The firm has yearly sales growth for the past five year of -7.90%. While past twelve months price to sales ratio recorded as 24.16 and price to cash ratio remained 14.30.
Should investors bet on ARIAD Pharmaceuticals, Inc. following this recent trend? Find Inside Facts Here